Nevro's HF10 Therapy Study for Non-Surgical Refractory Back Pain Underway
Nevro Corp. is conducting a multi-center, randomized study to evaluate the safety and effectiveness of HF10 Therapy for chronic refractory back pain.
Therapeutic Area
Therapeutic area intelligence for Neuromodulation with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.